Advanced search
Publication Cover
Acta Cardiologica Volume 78, 2023 - Issue 4
Submit an article Journal homepage
115
Views
1
CrossRef citations to date
0
Altmetric
Original Scientific Papers

18-Month effect of tafamidis on the progression of cardiac amyloidosis evaluated according to a multiparametric expert consensus tool

Osnat Itzhaki Ben Zadoka Department of Cardiology, Rabin Medical Center, Petah Tikva, Israel;b Faculty of Medicine, Tel Aviv University, Tel Aviv, IsraelCorrespondence[email protected]
View further author information
&
Ran Kornowskia Department of Cardiology, Rabin Medical Center, Petah Tikva, Israel;b Faculty of Medicine, Tel Aviv University, Tel Aviv, IsraelView further author information
Pages 417-422 | Received 31 Aug 2022, Accepted 07 Dec 2022, Published online: 04 Jan 2023

References

  • Garcia-Pavia P, Bengel F, Brito D, et al. Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy. Eur J Heart Fail. 2021;23(6):895–905.
  • Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007–1016.
  • McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC) with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J. 2021;42(36):3599–3726.
  • Patel RK, Fontana M, Ruberg FL. Cardiac amyloidosis: multimodal imaging of disease activity and response to treatment. Circ Cardiovasc Imaging. 2021;14(6):e009025.
  • Bézard M, Kharoubi M, Galat A, et al. Natural history and impact of treatment with tafamidis on major cardiovascular outcome-free survival time in a cohort of patients with transthyretin amyloidosis. Eur J Heart Fail. 2021;23(2):264–274.
  • Hanna M, Damy T, Grogan M, et al. Impact of tafamidis on Health-Related quality of life in patients with transthyretin amyloid cardiomyopathy (from the tafamidis in transthyretin cardiomyopathy clinical trial). Am J Cardiol. 2021;141:98–105.
  • Takase H, Dohi Y. Kidney function crucially affects B-type natriuretic peptide (BNP), N-terminal proBNP and their relationship. Eur J Clin Invest. 2014;44(3):303–308.
  • Thavendiranathan P, Grant AD, Negishi T, et al. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. J Am Coll Cardiol. 2013;61(1):77–84.
  • Itzhaki Ben Zadok O, Leshem-Lev D, Ben-Gal T, et al. The effect of tafamidis on circulating endothelial progenitor cells in patients with transthyretin cardiac amyloidosis. Cardiovasc Drugs Ther. 2021;36:489–496.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Novo Nordisk – Driving change to defeat serious chronic diseases.
Novartis. Your partner in Heart Failure & Atherosclerosis >>

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.